Interferon‐α alone probably leads to lower adverse events (grade ≥ 3) compared with interferon‐α plus bevacizumab (moderate certainty).
Interferon‐α alone may leads to higher adverse events (grade ≥ 3) compared with standard targeted therapies (sunitinib or temsirolimus) (low certainty).
The review found no eligible studies for this question.
Pegylated interferon plus ribavirin may leads to higher adverse events compared with pegylated interferon alone (low certainty).
Intravesically administered BCG alternating with IFN‐α showed no clear difference in discontinuation of therapy due to adverse events compared with intravesically administered BCG alone (low certainty).
The review found no eligible studies for this question.